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Abstract
The advent of laparoscopic surgery and with it Laparo-
scopic Ventral Mesh Rectopexy (LVMR) has revolution-
ised the management of internal ⁄ external rectal and
vaginal vault prolapse. These procedures have tradition-
ally been performed with synthetic meshes. Biologics
have gained a prominent role over the last decade in
LVMR as well as perineal procedures for rectocoele and
cystocoele repair. We examine the existing literature on
the use of biologics in pelvic floor surgery comparing this
with literature on synthetic mesh for the key outcomes of
infection rates, bowel ⁄ sexual function and recurrence.
Keywords Rectopexy, biologic, rectocoele, prolapse,
cystocoele
What is new in this paper?
This paper is the first synopsis of the published literature
on the use of biologics in the surgical treatment of pelvic
floor dysfunction.
Introduction
In the last decade, there has been a significant shift in the
debate about the best treatment for external rectal
prolapse from abdominal vs perineal approaches to ventral
vs posterior (resection) rectopexy to laparoscopic vs open
and now synthetic mesh vs biologics in ventral rectopexy.
It is now accepted that the abdominal approach is
superior to the perineal approach in terms of recurrence.
The advent of laparoscopic surgery has reduced the
morbidity of abdominal rectopexy and there is now
evidence to show it is safe in the elderly [1]. Recognition
of internal rectal prolapse as a pathological condition
contributing to the syndrome of obstructed defaecation
(ODS), and successful surgical treatment with laparo-
scopic ventral mesh rectopexy (LVMR) means that this
operation is being performed increasingly on a younger
cohort of patients.
Synthetic mesh was introduced into pelvic floor
surgery to reduce the high recurrence rate of up to
30%. Concerns about mesh erosion, infection and
dyspareunia then led to the introduction of biologic
meshes into pelvic floor surgery. The ideal mesh is one
that is flexible, shows good tissue integration, has low
infection rates, is biocompatible, chemically inert, non-
carcinogenic and non-allergenic [2]. It should also be
cost-effective and readily available.
There has also been a debate between advocates of
cross-linked vs non-cross linked biological meshes. Bio-
logical meshes work by acting as a collagen scaffold that
attracts fibroblasts and endothelial cells. A process of
remodeling ensues in which there is some degradation of
the biologic graft and regeneration of host tissue. The
balance of these two processes determines how much of
the graft is left. Some biologic meshes have additional
cross-links induced during the manufacturing process in
an attempt to slow down degradation. It is the cross-
linked type in the form of dermal porcine collagen that
has seen the greatest use in surgery for pelvic floor
dysfunction.
There is currently no consensus on the role of
biologics in the surgical management of pelvic organ
prolapse and obstructed defaecation. Biologics have been
traditionally used in infected fields in the context of
complex abdominal hernia or abdominal reconstruction
and have an established role in these cases. More recently
they have been used to close the perineum following
extra-levator abdomino-perineal excision (elAPE) of the
rectum.
The literature on biologics in pelvic floor surgery is
limited to case series (Table 1). There is a paucity of
randomized trials comparing synthetic to biologic mesh
or cross-linked vs non-cross-linked biological mesh. This
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review presents a synopsis of the existing literature on the
use of biologics in the surgical treatment of exter-
nal ⁄ internal rectal prolapse, rectocoele and other forms
of pelvic floor dysfunction.
Method
A literature search of published articles describing the use
of biologic mesh ⁄ graft in the surgical treatment of pelvic
organ prolapse and obstructed defaecation was con-
ducted. The key comparators between synthetic mesh
and biologics were functional outcome (Wexner Consti-
pation Scores, FISI, dyspareunia), mesh-related compli-
cations (erosion ⁄ infection) and recurrence.
Inclusion criteria were studies that described the use
of biologic material in the repair of external ⁄ full thick-
ness ⁄ internal rectal prolapse, internal intussusception,
vaginal vault prolapse, cystocoele, rectocoele, anterior
and posterior colporrhapy. Other search terms were
laparoscopic ventral rectopexy, sacrocolpopexy.
Results: abdominal
Laparoscopic ventral mesh rectopexy
Laparoscopic ventral mesh rectopexy has gained wide
acceptance as the surgical treatment of choice for external
rectal prolapse and internal intussusception associated
with obstructive defaecation. We examined publications
that describe the use of biological and synthetic mesh in
LVMR.
Bowel function
The first reported series of 65 patients (median follow-up
12 months) describing the use of Permacol (cross-
linked porcine dermal mesh) in LVMR for internal and
external rectal prolapse and vaginal vault prolapse,
showed results equivalent to synthetic mesh in the key
functional outcomes of constipation and incontinence.
There were statistically significant improvements in
Wexner Constipation Scores (WCS) and Vaizey scores
at 1 year (P < 0.0001 and P = 0.0002 respectively).
There were two cases of symptom but not clinical
recurrence in the internal rectal prolapse group (3.1%)
at a median follow up of 1 year. Symptoms in this UK
series, were rated as much better or better by 93% at
6 months and this was sustained at 1 year [3]. Updated
data from this series (n = 101, median follow-up
30 months; range 6–51 months) shows sustained
improvement in constipation (see Fig. 1). Mean WCS
was 3.8 (SD ± 4.2) and mean Vaizey scores of 1.1
(SD ± 2.2) in patients with at least 1-year follow-up.
Figure 2 shows a breakdown of the updated series by
indication for LVMR.
The second published series from Italy (mean follow-
up 12 months) described 34 consecutive patients that
underwent LVMR with Permacol for internal rectal
prolapse [4]. Nine patients (26%) had mixed ODS and
faecal incontinence. Constipation scores (median Wexner















Sileri et al. 2012 34 12 59 IRP Permacol 82% improved 73% improved 5
Wong et al. 2011 84 29 64 IRP Polyester 37% improved 4% improved 7.1
Collinson et al. 2010 72 12 58 IRP Polypropylene 86% improved 85% improved 5
Slawik et al. 2008 80 54 59 ERP, IRP,
SRU
Polypropylene 80% improved 91% improved 0 (full thickness
prolapse)
Auguste et al. 2006 54 53 ERP Synthetic 47% improved 69% improved 7.4%
D’Hoore &
Penninckx
























Figure 1 Wexner constipation scores pre-surgery, 6 months and
2 years after LVMR.
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score 15) and FI (median FISI score 12) improved
significantly at 3 months (Wexner 5, FISI 5, both
P < 0.001). Two patients experienced prolapse persis-
tence or recurrence. No patients had worsened bowel or
sexual function.
Updated data from the Italian series that now includes
57 patients shows functional outcomes similar to the
published data. Median Wexner constipation scores pre-
operatively were 15.1 compared to 5 at 12 months.
Faecal incontinence also improved from a median FISI
score of 9 to 2.5.
Sexual function
Twenty seven per cent of patients in the Italian series
reported dyspareunia preoperatively compared to 7.5% at
6 months (one new onset) and 5% at 12 months (the one
new onset patient had resolved). These results are sup-
ported by a paper from Abet et al. [5] who assessed sexual
function in a cohort of patients that had LVMR with
synthetic mesh using a questionnaire and found no de novo
dyspareunia. The levels of dyspareunia post-operatively
were also comparable to the general population. Eleven
patients (16.9%) in the UK series reported dyspareunia
prior to surgery. At 6 months follow up 3 ⁄ 40 had
dyspareunia (7.5%). This was a new symptom in one of
these patients and the other two were pre-existing. Two
patients with initial dyspareunia had symptoms at 1 year
but stated these were the same as before their surgery.
These results correlate with the Italian series.
Mesh-related complications
There were no cases of mesh erosion or mesh-related
infection in the two published series describing the use of
Permacol. There was one mesh related seroma that
required laparoscopic de-roofing 2 years after LVMR.
Rectal erosion has however been reported in laparoscopic
ventral rectopexy with synthetic mesh [6].
Non-mesh related complications
The published UK series described a general complica-
tion rate of 12.3% (8 ⁄ 65 patients). Most of these were
minor complications and only one required a return to
theatre following readmission for a port site hernia. The
overall complication rate was 23.5% (8 ⁄ 34 patients) in
the Italian series. Only one patient required a return to
theatre for adhesiolysis in this series.
Recurrence
The difficulty here is gauging the relevance of asymp-
tomatic clinical recurrence. The overall recurrence rate in
the UK series was 3.1%. Subset analysis shows a recur-
rence rate in the external rectal prolapse patients of 2.8%
(1 ⁄ 36), which compared favourably to another series
describing the use of synthetic mesh in LVMR for
external rectal prolapse [7]. The published data from the
Italian series included only patients that had LVMR with
Permacol for internal intussusception with a recurrence
rate of 5% (median follow up 12 months), which again
compares favourably with 3.7% from another series of
patients with internal intussusception describing the use
of synthetic mesh [8]. Interestingly, current data from
the Italian series shows an increase in recurrence rate to
19% with a minimum follow-up of 1 year. Recurrence
rate was 10.5% at 1 year and performing a Kaplan Meier
curve the risk of recurrence at 3 years follow-up was close
to 18%. The maximum peak of recurrences occurred
between 24 and 36 months after surgery, remaining
stable thereafter. Six out of 11 recurrences were observed
in the first 20 patients and the learning curve might be
responsible for these. It is also possible that early
recurrences or persistence of anatomical abnormalities
are secondary to technical failures, though a mesh-related
problem cannot be excluded. In the Gateshead series
there has been only one external rectal prolapse recur-
rence and this suggests that this is not a mesh-related
problem.
On further analysis, 8 out of eleven patients with
recurrences had previous hysterectomy. Nine out of
11 patients had redundant colon and 5 had concomitant
sigmoidopexy (overall sigmopidopexy was performed in
12 ⁄ 57 patients). These were all symptomatic recurrences
and confirmed by defaecating proctogram. Eight of these
patients have had STARR (one posterior and the others
circumferential) and the others are awaiting surgery.
Another series from Spain described a high recurrence
rate of 21% in sacrocolpopexy and LVMR using biolog-
ical grafts. This was however a heterogeneous series
covering disorders in all three pelvic floor compartments
and few patients actually had LVMR. Further analysis
showed all these patients had middle ⁄ anterior compart-
ment symptoms and only 9% required re-intervention
[9]. This paper raises the question of how clinical
recurrence is assessed. There appears to be poor corre-

























Figure 2 Indications for LMVR in gateshead series.
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Laparoscopic sacrocolpopexy
A review by the UK National Institute for Clinical
Excellence (NICE) compared sacrocolpopexy with syn-
thetic non-absorbable mesh to biological graft and found
mesh erosion occurred in 4% of women treated by
synthetic mesh compared with 0% of women who
received a biological graft (1-year follow-up) [10].
Reoperation for mesh-related complications was up to
9% (follow-up of 4–20 months).
The same review showed an objective failure rate
ranging from 0 to 6% for mesh sacrocolpopexy at an
average follow up of 2 years. The incidence of
subjective failure was however much higher (range
3–31%) with 2–14% requiring further surgery. This is in
keeping with data from LVMR series that show lower
re-intervention rates compared to the actual subjective
(symptom) recurrence rate. Of the 19 patients in the
UK series that had vault prolapse (Median follow-up
27 months; range 10–41 months), there have been




This approach was popularized in the decades leading up
to the development of laparoscopic colorectal surgery and
LVMR particularly. There is no reliable data about the
proportion of surgeons that still offer this approach to
their patients. There is data, however, to suggest that the
infection rate using Permacol is less (0%) compared
with synthetic mesh (13%). These results are from the
same unit using the same technique with different
meshes. They were neither randomised nor controlled
[11,12]. Synthetic absorbable mesh appears to have a
lower mesh erosion rate as exemplified by a series from
Turkey of 83 consecutive patients with a published
erosion rate of 0% following transperineal rectocoele
repair using polyglycolic acid mesh [13].
Transvaginal rectocoele repair
A NICE review (2008) of posterior vaginal repair for
rectocoele revealed a 0% erosion rate for biological grafts
(Permacol was used in the one trial that included
biologic grafts), 4% for combined synthetic ⁄ biologic and
7% for synthetic only [10]. Evidence from this review also
showed objective recurrence rate of 12.7% for procedures
without mesh ⁄ graft, 8.6% for absorbable synthetic mesh,
20.4% biological graft, and 6.5% for non-absorbable
synthetic mesh. Interestingly, there was no significant
difference in the re-intervention rates between the four
groups.
Cystocoele repair
A meta-analysis of four RCTs showed a significantly lower
objective recurrence rate (12%) with biological mesh were
compared to 23% without mesh [10]. Three of these
trials used Permacol while one used solvent-derived fascia
lata. Mesh erosion with biological grafts was 0% com-
pared to 6% with synthetic mesh though this was not
statistically significant. Figure 3 shows an anterior repair
being performed with Permacol.
Conclusion
Although there were no randomized trials comparing
synthetic to biological mesh, the available evidence
suggests biological grafts are safe and effective in the
surgical treatment of pelvic floor prolapse. The results in
the key outcomes of complications particularly mesh
erosion; recurrence, patient satisfaction, constipation and
incontinence are comparable to synthetic mesh.
One of the challenges we found in analysing the
available evidence is the variability between published
series in patient selection and outcomes measured. It is
difficult comparing the efficacy of the various procedures
used in pelvic floor surgery in terms of mesh vs no mesh
and biological vs synthetic mesh, as the comparators used
are different. Similar difficulty is encountered when
comparing objective and subjective recurrence rates
between the studies because the assessment tools vary.
LVMR is however performed using similar techniques in
all the published series we evaluated and this strengthens
our analysis.
One of the drawbacks of biological mesh is difficulty
handling the mesh in laparoscopic surgery. The authors
have found that aiming for the natural fenestrations in the
porcine graft (Permacol) with the needlepoint helps
overcome this. A useful tip published by one of the
Figure 3 Permacol in anterior vaginal repair.
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authors suggests using a sterile belt hole puncher to make
holes in the graft prior to insertion into the peritoneal
cavity [14].
The main drawback of biological grafts is the higher
cost when compared to synthetic mesh. Biological grafts
have gained an established role in surgery that involves
infected fields and we believe their use in pelvic floor
surgery could mitigate the potentially disastrous effects of
pelvic sepsis when synthetic mesh is sutured to the rectum.
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